PubMed Health⌕ Search

Biomedical subjects

J L Montero

Publications and source records attributed to J L Montero.

45 records · Page 3Linked to original sources
PubMed1977

Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours.

RFCNU or (chloro-2-ethyl)-l-(ribofuranosyl-isopropylidene-2', 3' paranitrobenzoate-5')-3 nitrosourea, a new synthetic nitrosourea derivative, which has been shown to have, in mice, among all nitrosourea derivatives tested, the longest maximallly efficient dose interval (MEDI) and which is not immunosuppressive at the smallest dose of MEDI, gave in a phase II trial on digestive tract tumours (at the dose of 400 mg/m2 per month determined by the phase I trial), 30% objective remissions among which 13% were greater than 50%.

Adolescent↗
PubMed1977

Effect of the nitrosourea derivative rpcnu (ICIG 1163) on the development of Friend leukemia in mice.

Friend leukemia was used as an experimental model to study the action of a ribofuranosyl derivative of nitrosourea : RPCNU. This new product was known to be active in L 1210 leukemia and immunosuppressive. RPCNU significantly decreases the splenomegaly induced in DBA2 mice by Friend virus when it is given at a time ranging from 7 days before to 14 days after virus inoculation. The survival time in leukemic treated groups is also greatly increased. However, viral content of the spleen extracts of the leukemic treated mice is not reduced. Therefore, RPCNU cannot be considered as an antiviral agent. A comparison between survival of leukemic and non leukemic mice treated with different doses show that the effectiveness of RPCNU is correlated with its toxicity. The effect of RPCNU on Friend leukemia by cytotoxicity on hematopoietic stem cells is discussed in this paper.

Animals↗
PubMed1975

The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals.

Four new nitrosourea derivatives represent an appreciable progress in the treatment and cure of L1210 leukemia. Their therapeutic index is higher than that of CCNU and MeCCNU. Of these compounds, RFCNU may prove the most promising, as its therapeutic index is the highest of those for all the four compounds studied; moreover, unlike the other products, it is not immunosuppressive, whether administered before or after the antigen.

Animals↗
PubMedDate not supplied

[Acute hepatitis due to ticlopidine. A report of 12 cases and review of the literature].

OBJECTIVE: To analyze the characteristics of hepatotoxicity due to ticlopidine. PATIENTS AND METHODS: We describe all the case of hepatotoxicity attributed to ticlopidine and reported to the Register of drug associated hepatopathies. We also obtained data from MEDLINE and the Spanish Medical Index regarding cases reported during the period 1982 2001. RESULTS: We reported twelve cases of hepatopathy related to the use of ticlopidine. These made up 5% of all the cases notified to the Register. Eighty three percent of the patients were male, and of an average age of 68 years. Sixty six percent required hospital admission. The latent period varied between 2 and 13 weeks. The liver lesion was of cholestatic type in 75% of the cases, hepatocellular in 16.6% and mixed in 8.3%. Twenty five percent of the patients had received sub therapeutic doses. CONCLUSIONS: Ticlopidine is often related to hepatotoxicity. This seems to be due to an idiosyncratic mechanism and is mainly cholestatic. The use of lower dosage than that recommended means that the desired therapeutic effect is not attained but does not protect against the development of hepatotoxicity. Doctors who use this drug should be aware of this so as to establish the true risk benefit relation.

Aged↗
PubMedDate not supplied

Gliclazide increases glucose utilization by rat intestine in vitro.

The effect of gliclazide (a hypoglycemic sulphonylurea; 200 micrograms/ml) on the absorption and utilization of glucose and lactate production was investigated by using an in vitro perfused intestine-pancreas preparation isolated from fed rats, after intraluminal or arterial glucose administration. In the absence of intraluminal glucose administration, both glucose utilization and lactate production seem to be dependent on the arterial glucose concentration. The glucose utilization by the intestine was significantly increased in the presence of gliclazide (200 micrograms/ml) at three arterial concentrations of glucose (2.75, 5.5 and 11.0 mmol/l) without increasing the lactate production. The translocation of glucose from the lumen to the blood after intraluminal sugar administration was reduced when the glucose concentration was increased in the perfusate. In the presence of gliclazide (200 micrograms/ml) the translocation of glucose from the lumen to the blood was significantly reduced at the three arterial concentrations of glucose without affecting the intestinal absorption rate. In conclusion, gliclazide 200 micrograms/ml, increases the metabolic utilization of both arterially or intraluminally supplied glucose in isolated and perfused rat intestine-pancreas.

Animals↗